Literature DB >> 29657199

Impact of body mass index on progression of primary immunoglobulin a nephropathy.

Shankar Prasad Nagaraju1, Dharshan Rangaswamy1, Aswani Srinivas Mareddy2, Srikanth Prasad1, Sindhu Kaza1, Srinivas Shenoy1, Karan Saraf1, Ravindra Prabhu Attur1, Rajeevalochana Parthasarathy3, Srinivas Kosuru4, Uday Venkat Mateti5, Vasudeva Guddattu6, Sindhura Lakshmi Koulmane Laxminarayana7.   

Abstract

The role of obesity in the progression of primary glomerular diseases is controversial. A few studies report overweight/obesity as a risk factor for disease progression in immunoglobulin A nephropathy (IgAN), and the real impact of it still remains unclear. The aim of this study was to elucidate the effect of body mass index (BMI) on disease progression and proteinuria in patients with IgAN in Indian population. A cohort of biopsy-proven primary IgAN patients diagnosed between March 2010 and February 2015 who had a follow-up for a minimum of 12 months were included in the study. We defined two groups of patients according to the BMI value at diagnosis: non-obese group (Group N) with BMI <23 Kg/m2 and the overweight/obese group (Group O) with BMI >23 Kg/m2 as per Asia-Pacific task force criteria. Baseline characteristics were compared between the groups. The estimated glomerular filtration rate (eGFR) and urine protein-creatinine ratio (UPCR) were followed up at entry time, 6 months, 12 months, and at the end of follow-up. Outcomes studied were change in eGFR, proteinuria, and progression to end-stage renal disease. Statistical analysis was done using the Statistical Package for the Social Sciences version 15.0. Of 51 patients, 25 (49%) had BMI <23 kg/m2 (Group N) and 26 (51%) had BMI >23 kg/m2 (Group O) (P = 0.01). The baseline clinical, histopathological, and treatment characteristics of both the groups were comparable. The BMI at the time of diagnosis did not have any significant effect on eGFR (P = 0.41) or proteinuria (P = 0.99) at presentation. At the end of follow-up, both the groups had a similar reduction of proteinuria (UPCR) (P = 0.46) and eGFR (P = 0.20). Two patients in each group have reached chronic kidney disease Stage 5. In the present study, BMI at presentation did not have any impact on eGFR or proteinuria, either at diagnosis or at follow-up. It needs further large multicenter randomized control studies to see the effect of BMI on progression of IgAN.

Entities:  

Mesh:

Year:  2018        PMID: 29657199     DOI: 10.4103/1319-2442.229261

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  3 in total

1.  Impact of body mass index on primary immunoglobulin A nephropathy prognosis: a systematic review and meta-analysis.

Authors:  Qin Wang; Jian-Jiang Zhang; Wen-Jie Dou; Hui-Qin Zeng; Pei-Pei Shi; Jing Wu
Journal:  Int Urol Nephrol       Date:  2021-08-12       Impact factor: 2.370

2.  Correlation of Body Mass Index with Clinicopathologic Parameters in Patients with Idiopathic Membranous Nephropathy.

Authors:  Xing Chen; Shuchun Chen; Zelin Li; Xiaoyu Pan; Yujiao Jia; Zhijuan Hu; Kai Niu; Bing Liu; Qingjuan Ren
Journal:  Diabetes Metab Syndr Obes       Date:  2022-06-20       Impact factor: 3.249

3.  Lipidomics reveals association of circulating lipids with body mass index and outcomes in IgA nephropathy patients.

Authors:  Yueyi Deng; Qingqing Wu; Wanjia Chen; Li Zhu; Wangyi Liu; Fangying Xia; Liang Sun; Xu Lin; Rong Zeng
Journal:  J Mol Cell Biol       Date:  2021-07-17       Impact factor: 6.216

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.